866-997-4948(US-Canada Toll Free)

Diabetic Neuropathy - Pipeline Review, H1 2014

Published By :

Global Markets Direct

Published Date : Mar 2014

Category :

Metabolic Disorders

No. of Pages : 81 Pages

Diabetic Neuropathy - Pipeline Review, H1 2014

Summary

Global Markets Directs, Diabetic Neuropathy - Pipeline Review, H1 2014, provides an overview of the Diabetic Neuropathys therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Diabetic Neuropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Neuropathy and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Diabetic Neuropathy
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Diabetic Neuropathy and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Diabetic Neuropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Diabetic Neuropathy pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Diabetic Neuropathy
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Diabetic Neuropathy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Diabetic Neuropathy Overview 8
Therapeutics Development 9
Pipeline Products for Diabetic Neuropathy Overview 9
Pipeline Products for Diabetic Neuropathy Comparative Analysis 10
Diabetic Neuropathy Therapeutics under Development by Companies 11
Diabetic Neuropathy Therapeutics under Investigation by Universities/Institutes 13
Diabetic Neuropathy Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Unknown Stage Products 17
Diabetic Neuropathy Products under Development by Companies 18
Diabetic Neuropathy Products under Investigation by Universities/Institutes 19
Diabetic Neuropathy Companies Involved in Therapeutics Development 20
Dainippon Sumitomo Pharma Co., Ltd. 20
Neuralstem, Inc. 21
Lpath, Inc. 22
DiaMedica Inc. 23
R-Tech Ueno, Ltd. 24
Neurotune AG 25
Intellect Neurosciences, Inc. 26
Glucox Biotech AB 27
Vascular Pharmaceuticals, Inc. 28
Relmada Therapeutics, Inc. 29
Dong-A Socio Holdings Co Ltd 30
Diabetic Neuropathy Therapeutics Assessment 31
Assessment by Monotherapy Products 31
Assessment by Target 32
Assessment by Mechanism of Action 35
Assessment by Route of Administration 38
Assessment by Molecule Type 40
Drug Profiles 42
ranirestat - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
ranirestat - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
DA-3030 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
DA-9801 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
atexakin alfa - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Lpathomab - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
NT-13317 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
RTU-1096 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
INN-01 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
NSI-566 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
mepivacaine hydrochloride - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Stromal Cell Therapy For Diabetic Complications - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
VPI-2690-B - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Angiotensin (1-7) peptide - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Small Molecule For Diabetic Neuropathy And Retinopathy - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
DM-433 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Small Molecule To Inhibit NOX-4 For Diabetic Neuropathy - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
BBI-21007 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Diabetic Neuropathy Recent Pipeline Updates 63
Diabetic Neuropathy Dormant Projects 72
Diabetic Neuropathy Discontinued Products 73
Diabetic Neuropathy Product Development Milestones 74
Featured News & Press Releases 74
Dec 02, 2013: Positive FDA Meeting Confirms BDSI Phase 3 Program for Clonidine Topical Gel for Treatment of Painful Diabetic Neuropathy 74
Sep 23, 2013: Lpath Awarded NIH SBIR Grant for Lpathomab 75
Mar 28, 2013: NeuroMax Receives Permission To Conduct Phase Ib Clinical Trial Of NM-IA-001 For Treatment Of Diabetic Polyneuropathy 75
Jan 30, 2013: NeuroMax Successfully Completes Phase Ia Clinical Trials Of NM-IA-001 In Patients With Diabetic Neuropathy 76
Nov 27, 2012: ChemoCentryx Announces Initiation Of Phase I Clinical Trial Of CCX872 76
Oct 15, 2012: Genkyotex Announces Presentation Of Data From Phase I Studies Of GKT137831 At Kidney Week 2012 77
May 10, 2012: NeuroMax Receives Authorization To Conduct Clinical Trials With NM-IA-001 In Russia 77
Mar 20, 2012: Astellas Pharma Europe Withdraws Its Applications For Extension Of Indication For Qutenza 78
Nov 07, 2011: NephroGenex Reaches Agreement With FDA On Subpart H Phase III Program For Pyridorin 78
Oct 31, 2011: J&JPRD Submits Supplemental New Drug Application To FDA For NUCYNTA ER Tablets For Diabetic Peripheral Neuropathic Pain 78
Appendix 80
Methodology 80
Coverage 80
Secondary Research 80
Primary Research 80
Expert Panel Validation 80
Contact Us 81
Disclaimer 81

List of Table

List of Tables
Number of Products under Development for Diabetic Neuropathy, H1 2014 9
Number of Products under Development for Diabetic Neuropathy Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 12
Number of Products under Investigation by Universities/Institutes, H1 2014 13
Comparative Analysis by Late Stage Development, H1 2014 14
Comparative Analysis by Clinical Stage Development, H1 2014 15
Comparative Analysis by Early Stage Development, H1 2014 16
Comparative Analysis by Unknown Stage Development, H1 2014 17
Products under Development by Companies, H1 2014 18
Products under Investigation by Universities/Institutes, H1 2014 19
Diabetic Neuropathy Pipeline by Dainippon Sumitomo Pharma Co., Ltd., H1 2014 20
Diabetic Neuropathy Pipeline by Neuralstem, Inc., H1 2014 21
Diabetic Neuropathy Pipeline by Lpath, Inc., H1 2014 22
Diabetic Neuropathy Pipeline by DiaMedica Inc., H1 2014 23
Diabetic Neuropathy Pipeline by R-Tech Ueno, Ltd., H1 2014 24
Diabetic Neuropathy Pipeline by Neurotune AG, H1 2014 25
Diabetic Neuropathy Pipeline by Intellect Neurosciences, Inc., H1 2014 26
Diabetic Neuropathy Pipeline by Glucox Biotech AB, H1 2014 27
Diabetic Neuropathy Pipeline by Vascular Pharmaceuticals, Inc., H1 2014 28
Diabetic Neuropathy Pipeline by Relmada Therapeutics, Inc., H1 2014 29
Diabetic Neuropathy Pipeline by Dong-A Socio Holdings Co Ltd, H1 2014 30
Assessment by Monotherapy Products, H1 2014 31
Number of Products by Stage and Target, H1 2014 34
Number of Products by Stage and Mechanism of Action, H1 2014 37
Number of Products by Stage and Route of Administration, H1 2014 39
Number of Products by Stage and Molecule Type, H1 2014 41
Diabetic Neuropathy Therapeutics Recent Pipeline Updates, H1 2014 63
Diabetic Neuropathy Dormant Projects, H1 2014 72
Diabetic Neuropathy Discontinued Products, H1 2014 73

List of Chart

List of Figures
Number of Products under Development for Diabetic Neuropathy, H1 2014 9
Number of Products under Development for Diabetic Neuropathy Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 11
Comparative Analysis by Clinical Stage Development, H1 2014 15
Comparative Analysis by Early Stage Products, H1 2014 16
Assessment by Monotherapy Products, H1 2014 31
Number of Products by Top 10 Target, H1 2014 32
Number of Products by Stage and Top 10 Target, H1 2014 33
Number of Products by Top 10 Mechanism of Action, H1 2014 35
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 36
Number of Products by Top 10 Route of Administration, H1 2014 38
Number of Products by Stage and Top 10 Route of Administration, H1 2014 39
Number of Products by Top 10 Molecule Type, H1 2014 40
Number of Products by Stage and Top 10 Molecule Type, H1 2014 41

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *